Ibrutinib, Fludarabine, Cyclophosphamide and Obinutuzumab ( iFCG) for Firstline Treatment of Patients with CLL with Mutated IGHV and without Del(17p)/ TP53 Mutation: Six-Year Follow-up AnalysesNitin Jain,Philip Thompson,Akhil Jain,Jan A. Burger,Alessandra Ferrajoli,Jayastu Senapati,Koichi Takahashi,Mahesh Swaminathan,Zeev Estrov,Gautam Borthakur,Prithviraj Bose,Tapan M. Kadia,Naveen Pemmaraju,Koji Sasaki, Divyam Bansal,Marina Y. Konopleva,Elias Jabbour,Naveen Garg,Xuemei Wang,Rashmi Kanagal-Shamanna,Keyur P. Patel,Wei Wang,Sa A. Wang, Jeffrey L. Jorgensen,Wanda Lopez,Ana Ayala,William Plunkett,Varsha Gandhi,Hagop M. Kantarjian, Susan M. O'Brien,Michael J. Keating,William G. WierdaBLOOD（2023）引用 0|浏览1暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
